Which statement about HbA1c as a clinical measure is true?

Which statement about HbA1c as a clinical measure is true?

• A. It measures immediate blood glucose levels.
• B. It reflects average glucose over the past 2-3 months.
• C. It is unaffected by hemoglobin variants.
• D. It is unchanged in hemolytic conditions.

Answer: (B)

HbA1c measures long-term glycemic exposure because glucose attaches to hemoglobin over the life of a red blood cell. Red blood cells live about 120 days, so HbA1c accumulates glucose exposure over roughly 8–12 weeks, i.e., about 2–3 months. That makes HbA1c a marker of average blood glucose over that period rather than the current moment. This is why the true statement is that HbA1c reflects the average glucose over the past 2–3 months. It does not measure immediate glucose, and its value can be affected by factors that alter red cell lifespan or by hemoglobin variants, which can interfere with some assay methods. For example, hemolytic conditions shorten red cell lifespan and can falsely lower HbA1c, while certain hemoglobin variants may cause assay interference and misleading results.

HbA1c measures long-term glycemic exposure because glucose attaches to hemoglobin over the life of a red blood cell. Red blood cells live about 120 days, so HbA1c accumulates glucose exposure over roughly 8–12 weeks, i.e., about 2–3 months. That makes HbA1c a marker of average blood glucose over that period rather than the current moment.

This is why the true statement is that HbA1c reflects the average glucose over the past 2–3 months. It does not measure immediate glucose, and its value can be affected by factors that alter red cell lifespan or by hemoglobin variants, which can interfere with some assay methods. For example, hemolytic conditions shorten red cell lifespan and can falsely lower HbA1c, while certain hemoglobin variants may cause assay interference and misleading results.